Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01395)
Name
Ripretinib
Synonyms    Click to Show/Hide the Synonyms of This API
1442472-39-0; DCC-2618; N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl}-N'-phenylurea; Ripretinib; Urea, N-[4-bromo-5-[1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6- naphthyridin-3-yl]-2-fluorophenyl]-N'-phenyl-39-0; Ripretinib free base; Ripretinib (DCC-2618); UNII-9XW757O13D; 9XW757O13D; Ripretinib (USAN); Ripretinib [USAN]; 1442472-39-0 (free base); 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea; Quinlock; Qinlock (TN); GTPL9175; CHEMBL4216467; SCHEMBL14999718; DCC2618; BCP29218; EX-A4883; s8757; DB14840; HY-112306; CS-0044835; D11353; DCC 2618;DCC2618;KIT/PDGFR inhibitor;Ripretinib; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
Clinical Status
Approved
PubChem CID
71584930
Formula
C24H21BrFN5O2
Canonical SMILES
CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
InChI
1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
InChIKey
CEFJVGZHQAGLHS-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=71584930"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 510.4 Topological Polar Surface Area 86.4
XlogP 4.1 Complexity 746
Heavy Atom Count 33 Rotatable Bond Count 5
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Ripretinib 50 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Crospovidone; Hypromellose Acetate Succinate; Lactose Monohydrate; Magnesium Stearate; Microcrystalline Cellulose; Silicon Dioxide
                   Dosage Form Tablet
                   Company Deciphera Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [1]
Crospovidone DIG Info Albendazole monooxygenase (Protein expression downregulation) [1]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [1]
References
1 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.